Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by RP Febrinasari
Cost-Effectiveness Analysis of Linagliptin Versus Sulfonylurea as Add-On Treatment to Metformin for the Treatment of Diabetes Mellitus Type 2 Patients in Indonesia
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-On Therapy to Metformin in Patients With Uncontrolled Type 2 Diabetes Mellitus
Diabetes Therapy
Internal Medicine
Endocrinology
Metabolism
Diabetes
Cost-Effectiveness of Dapagliflozin Versus DPP-4 Inhibitors as an Add-On to Metformin in the Treatment of Type 2 Diabetes Mellitus From a UK Healthcare System Perspective
BMC Health Services Research
Health Policy
Dapagliflozin: Cost-Effectiveness as an Add-On Therapy to Metformin in the Treatment of Type 2 Diabetes (T2DM) in Argentina and Chile
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost-Effectiveness of Dapagliflozin as Add-On to Insulin for the Treatment of Type 2 Diabetes in the Netherlands
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost Effectiveness Evaluation of Canagliflozin in Combination With Metformin in the Treatment of Type 2 Diabetes Mellitus in Poland
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost-Minimization Analysis of Linagliptin Compared to Sitagliptin in the Treatment of Type 2 Diabetes Mellitus From a Turkish Healthcare Perspective
Journal of Diabetes & Metabolism
Cost-Utility Analysis of Liraglutide Compared With Sulphonylurea or Sitagliptin, All as Add-On to Metformin Monotherapy in Type 2 Diabetes Mellitus
Diabetic Medicine
Internal Medicine
Endocrinology
Metabolism
Diabetes
Comparison of Antioxidative Effect of Metformin and Combination of Metformin-Sulfonylurea in Type 2 Diabetes Mellitus Patients
Journal of Young Pharmacists
Toxicology
Pharmaceutics
Pharmacology
Metformin as First-Line Treatment for Type 2 Diabetes
The Lancet
Medicine
